News MSD starts pivotal trial of ROR1 drug in first-line lymphoma MSD has started a phase 3 trial of ROR1-directed ADC zilo-V as a treatment for previously untreated diffuse large B-cell lymphoma.
News ASH: MSD’s ROR1 drug hits the target in first-line lymphoma The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.
News Abivax climbs on Lilly takeover speculation Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.